19 reports of this reaction
1.7% of all MENTHOL, METHYL SALICYLATE reports
#14 most reported adverse reaction
APPLICATION SITE BURN is the #14 most commonly reported adverse reaction for MENTHOL, METHYL SALICYLATE, manufactured by Hisamitsu Pharmaceutical Co., Inc.. There are 19 FDA adverse event reports linking MENTHOL, METHYL SALICYLATE to APPLICATION SITE BURN. This represents approximately 1.7% of all 1,107 adverse event reports for this drug.
Patients taking MENTHOL, METHYL SALICYLATE who experience application site burn should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APPLICATION SITE BURN is a less commonly reported adverse event for MENTHOL, METHYL SALICYLATE, but still significant enough to appear in the safety profile.
In addition to application site burn, the following adverse reactions have been reported for MENTHOL, METHYL SALICYLATE:
The following drugs have also been linked to application site burn in FDA adverse event reports:
APPLICATION SITE BURN has been reported as an adverse event in 19 FDA reports for MENTHOL, METHYL SALICYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
APPLICATION SITE BURN accounts for approximately 1.7% of all adverse event reports for MENTHOL, METHYL SALICYLATE, making it a notable side effect.
If you experience application site burn while taking MENTHOL, METHYL SALICYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.